Novelion Therapeutics Reports Preliminary Fourth Quarter & Full Year 2016 Financial Results
Mar 15, 2017 11:01 am UTC| Business
Company Reiterates FY 2017 Total Net Product Sales Expected to beBetween $155 and $165 millionGlobal Expansion Plans for Metreleptin Opportunity Underway VANCOUVER, British Columbia, March 15, 2017 -- Novelion...
Novelion Therapeutics Reports Preliminary Fourth Quarter & Full Year 2016 Financial Results
Mar 15, 2017 11:01 am UTC| Business
Company Reiterates FY 2017 Total Net Product Sales Expected to beBetween $155 and $165 millionGlobal Expansion Plans for Metreleptin Opportunity Underway VANCOUVER, British Columbia, March 15, 2017 -- Novelion...
Mar 15, 2017 11:01 am UTC| Business
TNX-102 SL, a Drug in Phase 3 Development, Recently Granted Breakthrough Therapy Designation by the FDA Pivotal Study in Military-Related PTSD to Begin this Month NEW YORK, March 15, 2017 -- Tonix Pharmaceuticals...
Mar 15, 2017 11:01 am UTC| Business
TNX-102 SL, a Drug in Phase 3 Development, Recently Granted Breakthrough Therapy Designation by the FDA Pivotal Study in Military-Related PTSD to Begin this Month NEW YORK, March 15, 2017 -- Tonix Pharmaceuticals...
Mar 15, 2017 11:01 am UTC| Business
WATERTOWN, Mass., March 15, 2017 -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, today announced that an abstract supporting the Company’s...
Mar 15, 2017 11:01 am UTC| Business
WATERTOWN, Mass., March 15, 2017 -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, today announced that an abstract supporting the Company’s...
Anavex Life Sciences to Present at Oppenheimer 27th Annual Healthcare Conference
Mar 15, 2017 11:01 am UTC| Business
NEW YORK, March 15, 2017 -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative...